Thomas Jefferson University

1. Amgen Inc. $7,296,392 86 payments
2. AbbVie, Inc. $4,565,912 193 payments
3. Merck Sharp & Dohme Corporation $3,057,765 120 payments
4. Eli Lilly and Company $2,803,149 137 payments
5. Janssen Research & Development, LLC $2,621,902 244 payments
6. Exelixis Inc. $1,826,728 182 payments
7. Medivation Inc. $1,795,855 224 payments
8. Genentech, Inc. $1,751,938 162 payments
9. Celgene Corporation $1,515,143 40 payments
10. Pfizer Inc. $1,469,323 256 payments

1. A Phase I/II Study of venetoclax (ABT-199) in Combination with Liposomal Vincristine for Relapsed/Refractory T-cell or B-Cell Acute Lymphoblastic Leukemia $3,180,366 2 payments
2. AMG 509_Prostate Cancer_20180146. $2,359,507 22 payments
3. AMG 510 Ph1b Master Protocol 20190135 $1,543,565 7 payments
4. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $1,526,079 35 payments
5. A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cance $1,253,810 2 payments
6. Specimen Collection Study from HIV-Infected Adults for Laboratory Research $946,843 15 payments
7. Neoadjuvant REGN2810 (Cemiplimab) in cutaneous basal cell carcinoma of the head and neck $740,346 16 payments
8. Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors $730,836 32 payments
9. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $666,991 17 payments
10. EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma $546,625 16 payments

1. Patient care $269,156 29 payments
2. Other $104,117 10 payments
3. Non-patient care $47,125 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.